Which is better, BRKRP or GMAB?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than BRKRP — 65/100 (C grade) vs 38/100 (D). That said, "better" depends on which framework you trust — BRKRP wins on Peter Lynch; GMAB wins on Warren Buffett, Benjamin Graham, Philip Fisher, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy BRKRP or GMAB?

This page is an educational comparison, not investment advice. Both BRKRP and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is BRKRP better than GMAB for value investing?

On the Buffett-style value-investing framework, GMAB currently grades higher — 65/100 vs 38/100, a 27-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between BRKRP and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). BRKRP currently scores 38/100 (D grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, BRKRP or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. BRKRP and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, BRKRP or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are BRKRP and GMAB both Healthcare stocks?

Yes — both Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this BRKRP vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

BRKRP

Market cap

$53.05B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	BRKRP	GMAB	Winner
Warren Buffett	38D	65C	GMAB
Benjamin Graham	45D	64C	GMAB
Philip Fisher	38D	48D	GMAB
Peter Lynch	30F	25F	BRKRP
Joel Greenblatt	42D	76B	GMAB
Charlie Munger	40D	68C	GMAB
Terry Smith	38D	71C	GMAB

Side-by-side metrics

Metric	BRKRP	GMAB
Market cap	$53.05B	$16.5B
P/E (TTM)	-	6.2x
EV/EBIT	59.6x	12.0x
ROIC (TTM)	-2.92%	43.78%
Gross margin	45.56%	93.88%
Net margin	-0.34%	18.23%
Revenue CAGR 5y	9.19%	-18.45%
EPS CAGR 5y	-	-23.48%
Debt / Equity	0.7x	0.1x
Dividend yield	0.45%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

BRKRP leads on

Revenue CAGR 5y9.19%vs -18.45%+150%
P/E (TTM)-vs 6.2x+101%
Dividend yield0.45%vs 0.0%+100%
Market cap$53.05Bvs $16.5B+69%

GMAB leads on

ROIC (TTM)43.78%vs -2.92%+107%
Net margin18.23%vs -0.34%+102%
Debt / Equity0.1xvs 0.7x+89%
EV/EBIT12.0xvs 59.6x+80%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A

Genmab A/S

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like BRKRP

More like GMAB

Related on invest-like

Key terms in this analysis